Hayat Pharmaceutical Industries Co's EBIT per Share for the
three
months ended in Mar. 2026 was JOD0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was JOD0.27.
During the past 12 months, the average EBIT per Share Growth Rate of Hayat Pharmaceutical Industries Co was -38.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -16.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -10.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
AMM:HPIC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -16.2 Med: -4.15 Max: 9.8
Current: -16.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Hayat Pharmaceutical Industries Co was 9.80% per year. The lowest was -16.20% per year. And the median was -4.15% per year.
AMM:HPIC's 3-Year EBIT Growth Rate is ranked worse than 81.85% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs AMM:HPIC: -16.20
Hayat Pharmaceutical Industries Co (AMM:HPIC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hayat Pharmaceutical Industries Co EBIT per Share Related Terms
Hayat Pharmaceutical Industries Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hayat Pharmaceutical Industries Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD0.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a EBIT per Share of JOD0.27 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hayat Pharmaceutical Industries Co and its competitors. According to the industry distribution chart, Hayat Pharmaceutical Industries Co ranks #663 out of 810 companies in the Drug Manufacturers industry, placing it in the top 81.9%.
Is Hayat Pharmaceutical Industries Co's EBIT per Share too high?
Hayat Pharmaceutical Industries Co's current EBIT per Share is JOD0.27. Based on the distribution chart, Hayat Pharmaceutical Industries Co ranks #663 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hayat Pharmaceutical Industries Co ranks #663 out of 810 companies for EBIT per Share. This places Hayat Pharmaceutical Industries Co in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hayat Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hayat Pharmaceutical Industries Co's current EBIT per Share is JOD0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.20 — trading 16.8% above its estimated fair value. The current EBIT per Share is JOD0.27. Hayat Pharmaceutical Industries Co's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current EBIT per Share is JOD0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued.
The current stock price of JOD3.20 is trading 16.8% above its estimated GF Value™ of JOD2.74.
GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.
Key valuation signals for AMM:HPIC:
EBIT per Share: JOD0.27
GF Value™: JOD2.74 vs. price of JOD3.20 (16.8% above fair value)
No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hayat Pharmaceutical Industries Co Business Description
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
76GF Score
Get the complete analysis for AMM:HPIC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:HPIC has been successfully added to your 
